INSIGHTS

Amid rapid scientific progress, familiar targets continue to capture momentum while promising alternatives struggle for visibility. A quiet cognitive bias shapes how opportunities are assessed and prioritized. For companies developing novel science, recognizing this pattern—and designing strategies that anticipate and counter it—will be essential to advancing differentiated programs in a landscape defined by precedent.

Patient journey mapping has transformed how life sciences companies understand and serve patients—but most maps miss a crucial voice: the caregiver. By expanding mapping to capture real-time, diverse patient experiences and integrating caregiver perspectives, companies can design more relevant trials, value-based products, and compelling launch narratives. Including those who guide patients through care not only humanizes development but drives adherence, satisfaction, and co

Federal grant volatility is disrupting early-stage biotech, with programs like CDMRP facing steep cuts and new NIH restrictions limiting access. As delays and cancellations increase, traditional budgeting falls short. This piece explores how scenario-based FP&A helps companies navigate uncertainty, prioritize pipelines, and sustain innovation in a shifting funding landscape.

Pharma’s sales model is shifting toward a strategic hybrid: balancing digital convenience with the enduring influence of in-person engagement. While digital channels offer scalable, flexible access, face-to-face interactions remain the most effective for influencing prescribing behavior. The key to success lies in tailoring the right channel to the right context: drug type, physician preference, and market dynamics all matter.

A fragmented KOL engagement approach can damage credibility, strain relationships, and lead to missed insights. This article explores the value of a harmonized strategy that aligns Medical Affairs, Clinical Development, and Commercial teams to ensure consistent, strategic interactions. It also highlights the rise of Digital Opinion Leaders and the need to engage emerging voices. A coordinated approach not only builds trust with experts but also drives better outcomes and long

The Trump administration is doubling down on its promise of pharmaceutical tariffs, designed to re-shore manufacturing and protect strategic interests. What would it mean for biopharma? More importantly, what would it mean for patients? In this article, we summarize existing perspectives and dive into some less-explored topics, such as clinical trial execution, budget management, and early-stage investment.